The latest update is out from Precigen ( (PGEN) ).
Precigen, Inc. has reclaimed all rights to its technology following the termination of its Amended and Restated License Agreement with Alaunos Therapeutics, Inc., effectively revoking any access Alaunos once had. This marks a significant shift in control over the licensed technology since the original agreement in 2018.
Learn more about PGEN stock on TipRanks’ Stock Analysis page.
